CytomX Therapeutics, Inc.

NasdaqGS:CTMX Stock Report

Market Cap: US$85.3m

CytomX Therapeutics Future Growth

Future criteria checks 0/6

CytomX Therapeutics's revenue and earnings are forecast to decline at 17.2% and 39.9% per annum respectively while EPS is expected to decline by 41% per annum.

Key information

-39.9%

Earnings growth rate

-41.0%

EPS growth rate

Biotechs earnings growth27.5%
Revenue growth rate-17.2%
Future return on equityn/a
Analyst coverage

Good

Last updated21 Nov 2024

Recent future growth updates

Recent updates

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry

Dec 17
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

Oct 26
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues

CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments

Jul 15

The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

Jun 15
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%

We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

May 09
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now

CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling

May 02

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 27
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 25

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

Mar 05
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Jan 19
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Nov 26
There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Nov 17
We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 29
Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Feb 13
Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

CytomX Therapeutics to cut workforce by about 40%

Jul 13

CytomX says phase 2 study of breast cancer antibody treatment met main goal

Jul 06

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Jun 08
Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

Feb 10
Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

CytomX: Pullbacks Are Opportunities

Dec 14

Earnings and Revenue Growth Forecasts

NasdaqGS:CTMX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202645-76-28N/A3
12/31/202581-32-13-406
12/31/2024116-8-50-696
9/30/202412714-89-88N/A
6/30/202412011-86-86N/A
3/31/202411917-92-91N/A
12/31/2023101-1-57-56N/A
9/30/202395-10-36-35N/A
6/30/202379-42-52-51N/A
3/31/202368-71-61-60N/A
12/31/202253-99-113-111N/A
9/30/202221-149-142-141N/A
6/30/202227-143-138-136N/A
3/31/202230-132-132-130N/A
12/31/202137-116-121-119N/A
9/30/202166-72-107-105N/A
6/30/202166-64-103-100N/A
3/31/202167-612325N/A
12/31/202068-6535N/A
9/30/202092-54-9-7N/A
6/30/202085-63-8-5N/A
3/31/202078-76-154-151N/A
12/31/201927-133-144-140N/A
9/30/201961-99-144-140N/A
6/30/201962-99-126-122N/A
3/31/201975-83-105-100N/A
12/31/201860-85-79-76N/A
9/30/201875-52-28-25N/A
6/30/201887-39N/A-25N/A
3/31/201874-50N/A175N/A
12/31/201772-43N/A170N/A
9/30/201751-58N/A150N/A
6/30/201730-62N/A142N/A
3/31/201724-51N/A-16N/A
12/31/201615-59N/A-2N/A
9/30/201611-57N/A-12N/A
6/30/20169-57N/A-6N/A
3/31/20168-50N/A-28N/A
12/31/20158-42N/A-27N/A
9/30/20158-36N/A-24N/A
6/30/20158-26N/A30N/A
3/31/20156-24N/A31N/A
12/31/20145-35N/A32N/A
12/31/20131-19N/A-8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CTMX's earnings are forecast to decline over the next 3 years (-39.9% per year).

Earnings vs Market: CTMX's earnings are forecast to decline over the next 3 years (-39.9% per year).

High Growth Earnings: CTMX's earnings are forecast to decline over the next 3 years.

Revenue vs Market: CTMX's revenue is expected to decline over the next 3 years (-17.2% per year).

High Growth Revenue: CTMX's revenue is forecast to decline over the next 3 years (-17.2% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CTMX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:35
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CytomX Therapeutics, Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Etzer DaroutBMO Capital Markets Equity Research
Ying HuangBofA Global Research